



MEDIA RELEASE

SAHPRA Responds to the ANHP Judgement

Embargo: Immediate release

Pretoria, 20 April 2022: The South Africa Health Products Regulatory Authority (SAHPRA) notes the ruling by the Supreme Court of Appeal (SCA) in favour of the Alliance of Natural Health Products in South Africa (ANHP) on 11 April 2022.

SAHPRA is studying this judgement and consulting with the legal team before a full statement is issued. Once we arrive at a decision, all industry stakeholders and the public will be informed as to the way forward.

Issued by:

Dr Boitumelo Semete

CEO

Boitumelo.semete@sahpra.org.za

For further enquiries /information contact:

Media contact:

Ms Nthabi Moloji

Cell: 082 407 8854

E-mail: Nthabi.moloi@sahpra.org.za

About SAHPRA:

SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting and registering) all health products. This includes clinical trials, complementary medicines, medical devices and in-vitro diagnostics (IVDs). Furthermore, SAHPRA has the added responsibility of overseeing radiation control in South Africa. SAHPRA's mandate is outlined in the Medicines and Related Substances Act (Act No 101 of 1965 as amended) as well as the Hazardous Substances Act (Act No 15 of 1973).

SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa:

- Safety
- Efficacy
- Quality

It is these three pillars that define the ethos of SAHPRA.